Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours
- PMID: 8484983
- DOI: 10.1016/s0959-8049(05)80431-9
Immunochemical analysis of the p53 oncoprotein in matched primary and metastatic human tumours
Abstract
There is much interest in the range of genetic aberrations which occur in human malignancies. An immunohistochemical study has been carried out to investigate the consistency of expression of abnormally accumulated p53 protein in paired samples of archival primary and metastatic carcinomas. The staining of methacarn-fixed tissue from 136 matched pairs of mammary carcinoma and 20 cancers from other sites was completed using antibody CM-1 and DO1 in a sensitive peroxidase-conjugated streptavidin-biotin technique. The majority of tumour cells were positive in 25% and the tumours were negative in 17% of the primary carcinomas; staining was heterogeneous in the remaining cases. Staining was identical in 180/186 (96%) metastatic lesions. An ELISA assay carried out on 12 matched pairs of the tumour specimens demonstrated that altered conformation of the aberrant p53 protein present in a primary lesion was maintained in its metastasis. These data indicate that alterations in the p53 gene result in a relatively stable phenotype and that progression of disease is not usually accompanied by either further mutation or loss of the mutant allele.
Similar articles
-
Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies.Oncogene. 1991 Sep;6(9):1699-703. Oncogene. 1991. PMID: 1923535
-
Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression.J Pathol. 1994 Sep;174(1):23-31. doi: 10.1002/path.1711740105. J Pathol. 1994. PMID: 7965400
-
Expression of p53 protein in infiltrating and in-situ breast carcinomas.J Pathol. 1991 Nov;165(3):203-11. doi: 10.1002/path.1711650303. J Pathol. 1991. PMID: 1684809
-
Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation.Br J Cancer. 1994 Jan;69(1):26-31. doi: 10.1038/bjc.1994.4. Br J Cancer. 1994. PMID: 7506924 Free PMC article.
-
The clinical significance of p53 aberrations in human tumours.Virchows Arch. 1995;427(3):229-41. doi: 10.1007/BF00203389. Virchows Arch. 1995. PMID: 7496591 Review.
Cited by
-
p53 protein is absent from the serum of patients with lung cancer.Br J Cancer. 1996 Nov;74(9):1434-40. doi: 10.1038/bjc.1996.561. Br J Cancer. 1996. PMID: 8912541 Free PMC article.
-
The Carolina Breast Cancer Study: integrating population-based epidemiology and molecular biology.Breast Cancer Res Treat. 1995 Jul;35(1):51-60. doi: 10.1007/BF00694745. Breast Cancer Res Treat. 1995. PMID: 7612904
-
Biological indices in the assessment of breast cancer.Clin Mol Pathol. 1995 Oct;48(5):M221-38. doi: 10.1136/mp.48.5.m221. Clin Mol Pathol. 1995. PMID: 16696013 Free PMC article. No abstract available.
-
Detection of p53 in inflammatory tissue and lymphocytes using immunohistology and flow cytometry: a critical comment.J Clin Pathol. 1997 Aug;50(8):654-60. doi: 10.1136/jcp.50.8.654. J Clin Pathol. 1997. PMID: 9301548 Free PMC article.
-
Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.Cancer Cell. 2008 May;13(5):454-63. doi: 10.1016/j.ccr.2008.03.004. Cancer Cell. 2008. PMID: 18455128 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous